Press

Numinus Expands Ketamine Therapy for Mental Health in Montreal and announces new brand awareness initiatives

Sep 22 • 3 min read

Numinus Wellness Inc. (TSX: NUMI | OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced the opening of a new clinic in Montreal that will replace an existing downtown clinic. The new site, in the Plateau neighbourhood, will have expanded capacity to offer ketamine treatments, including a wider assortment of ketamine-assisted…

Universal Ibogaine Announces Kelburn Reopening Date

Sep 22 • 2 min read

Universal Ibogaine Inc.(TSXV:IBO), a life sciences company with a mission to deliver medicalized ibogaine-centered addiction care, advises that it’s research and development clinic, the Kelburn Mental Health and Addiction Recovery Center is scheduled to reopen and commence business operations on October 17, 2022 . “Progress is going remarkably well on the renovations and program development, we have key hires…

Braxia Scientific Announces Board Appointment

Sep 22 • 2 min read

Braxia Scientific Corp, (CSE: BRAX | OTC: BRAXF | FWB: 4960) a medical research and telemedicine company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, is pleased to announce that Leann Taylor, President and COO of KetaMD, Inc., has joined the board of directors. KetaMD, a telemedicine platform recently acquired by…

Algernon Pharmaceuticals Announces Receipt of CDN $450K Cash Refund from Australian Research Program

Sep 21 • 2 min read

Algernon Pharmaceuticals Inc. (CSE: AGN | FRANKFURT: AGW | OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that it has recently received a cash payment of approximately CDN $450K from a refundable tax credit program from its clinical research work in Australia. “Algernon tries to conduct as much of its clinical research in Australia as possible…

Biomind Labs Announces Completion of Dosing in Phase II Trial of Its DMT-Based Inhaled Formulation BMND01 for Treatment-Resistant Depression

Sep 21 • 2 min read

Biomind Labs Inc. (NEO: BMND | OTC: BMNDF | FSE: 3XI), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological and psychiatric disorders by scientifically harnessing the medicinal power of psychedelic molecules, is pleased to announce the completion of dose administration of 30 healthy subjects in…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441442443444445446447448449450451452453454455456457458459460461462463